Carpenter Technology Corporation (CRS)
NYSE: CRS · Real-Time Price · USD
573.19
-3.68 (-0.64%)
Jul 15, 2026, 9:55 AM EDT - Market open
Carpenter Technology Employees
Carpenter Technology had 4,500 employees as of June 30, 2025. The number of employees decreased by 100 or -2.17% compared to the previous year.
Employees
4,500
Change (1Y)
-100
Growth (1Y)
-2.17%
Revenue / Employee
$673,067
Profits / Employee
$106,422
Market Cap
28.48B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 4,500 | -100 | -2.17% |
| Jun 30, 2024 | 4,600 | 100 | 2.22% |
| Jun 30, 2023 | 4,500 | 400 | 9.76% |
| Jun 30, 2022 | 4,100 | 200 | 5.13% |
| Jun 30, 2021 | 3,900 | -700 | -15.22% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Commercial Metals Company | 12,690 |
| ESAB Corporation | 10,300 |
| ATI Inc. | 7,600 |
| Mueller Industries | 4,832 |
| Ryerson Holding | 4,300 |
| Worthington Enterprises | 3,400 |
| Mayville Engineering Company | 2,400 |
| Proto Labs | 2,280 |
CRS News
- 2 hours ago - Sales Gains Send Carpenter Technology Higher Before Earnings Report - FXEmpire
- 1 day ago - JPMorgan ups Carpenter target, places on ‘Negative Catalyst Watch’ - TheFly
- 1 day ago - Billionaires are loading up on these superior stocks. Why it pays to follow their money. - Market Watch
- 2 days ago - Carpenter Technology price target raised to $650 from $470 at TD Cowen - TheFly
- 6 days ago - Carpenter Technology price target raised to $680 from $495 at Susquehanna - TheFly
- 14 days ago - Carpenter Technology Announces Conference Call and Webcast - GlobeNewsWire
- 4 weeks ago - Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partner - GlobeNewsWire
- 5 weeks ago - Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 - Business Wire